Can Genetic Testing Predict Opioid Addiction Risk?

| December 16, 2019

article image
Prescient Medicine Holdings, Inc. and the Department of Clinical Chemistry at Erasmus MC (CC-EMC), Rotterdam announced a partnership for CC-EMC to study opioid addiction risk in The Netherlands. The partnership will center on Prescient Medicine's novel genetic testing technology designed to objectively assess an individual's risk of opioid addiction prior to opioid exposure. The clinical research will be conducted with patients in The Netherlands to confirm that the positive results from research completed in the United States are also found in the Dutch health care system. According to a 2019 study, the overall number of prescription opioid users in the Netherlands has nearly doubled between 2008 and 2017, and the number of opioid-related hospital admissions has tripled.

Spotlight

NANO DISCOVERY, INC.

Nano Discovery Inc. is a biotechnology company based in Orlando, Florida, United States. Nano Discovery developed, manufactures and sells single-step and washing-free immunoassay technology, D2Dx™. D2Dx™ is a platform technology that can be used for the detection and analysis of both antibody and antigen proteins. Using the conjugation kits and assay reader from Nano Discovery, any immunoassay can be customized to specific needs within hours. D2Dx™ immunoassay is simple to use with assay results obtained within 5-30 minutes. Nano Discovery’s unique technology and methodology were developed by Dr. Qun (Treen) Huo at the University of Central Florida’s Department of Chemistry and NanoScience Technology Center. Huo used a variety of UCF’s Tech Transfer programs in creating Nano Discovery Inc. at the UCF Business Incubator. The company is led by biotechnology entrepreneur and investor Davian Santana. For more information visit www.nanodiscoveryinc.com and follow us on Twitter @nanodiscover

OTHER ARTICLES

Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020

Article | February 24, 2020

The year 2020 marks a decade since the term pharmacomicrobiomics was coined (Rizkallah et al., 2010) to crystallize a century-old concept of mutual interactions between humans, drugs, and the microbial world. The human microbiome, with its immense metabolic potential that exceeds and expands the human metabolic capacities, has the ability to modulate pharmacotherapy by affecting both pharmacokinetics and pharmacodynamics of drug molecules:

Read More

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | February 18, 2020

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Top 10 biotech IPOs in 2019

Article | February 24, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Making Predictions by Digitizing Bioprocessing

Article | April 20, 2021

With advances in data analytics and machine learning, the move from descriptive and diagnostic analytics to predictive and prescriptive analytics and controls—allowing us to better forecast and understand what will happen and thus optimize process outcomes—is not only feasible but inevitable, according to Bonnie Shum, principal engineer, pharma technical innovation, technology & manufacturing sciences and technology at Genentech. “Well-trained artificial intelligence systems can help drive better decision making and how data is analyzed from drug discovery to process development and to manufacturing processes,” she says. Those advances, though, only really matter when they improve the lives of patients. That’s exactly what Shum expects. “The convergence of digital transformation and operational/processing changes will be critical for the facilities of the future and meeting the needs of our patients,” she continues. “Digital solutions may one day provide fully automated bioprocessing, eliminating manual intervention and enabling us to anticipate potential process deviations to prevent process failures, leading to real-time release and thus faster access for patients.” To turn Bioprocessing 4.0 into a production line for precision healthcare, real-time release and quickly manufacturing personalized medicines will be critical. Adding digitization and advanced analytics wherever possible will drive those improvements. In fact, many of these improvements, especially moving from descriptive to predictive bioprocessing, depend on more digitization.

Read More

Spotlight

NANO DISCOVERY, INC.

Nano Discovery Inc. is a biotechnology company based in Orlando, Florida, United States. Nano Discovery developed, manufactures and sells single-step and washing-free immunoassay technology, D2Dx™. D2Dx™ is a platform technology that can be used for the detection and analysis of both antibody and antigen proteins. Using the conjugation kits and assay reader from Nano Discovery, any immunoassay can be customized to specific needs within hours. D2Dx™ immunoassay is simple to use with assay results obtained within 5-30 minutes. Nano Discovery’s unique technology and methodology were developed by Dr. Qun (Treen) Huo at the University of Central Florida’s Department of Chemistry and NanoScience Technology Center. Huo used a variety of UCF’s Tech Transfer programs in creating Nano Discovery Inc. at the UCF Business Incubator. The company is led by biotechnology entrepreneur and investor Davian Santana. For more information visit www.nanodiscoveryinc.com and follow us on Twitter @nanodiscover

Events